The latest approval is the use of tremelimumab (anti-CTLA4) in combination with durvaluman (anti-PD-L1) and platinum for patients with metastatic NSCLC, on 10 November 2022 (https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-and-platinum-based-chemotherapy-metastatic-non) (accessed on 12 December 2022). This evidence concerns the gene CD274 and non-small cell lung carcinoma.